Intelligent Ultrasound Group plc
("the Company")
Grant of Share Options
Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound artificial intelligence (AI) software and simulation company, announces the grant of 2,649,015 share options to the Directors and 6,800,332 share options to other management and employees (together the "options") on 21 December 2023 at a price of 9.6 pence per share, representing the closing mid-market price on 20 December 2023, the date of approval by the Remuneration Committee.
Individual Director option grants
| Director | New grant | Type |
| Stuart Gall | 530,428 | EMI |
| Stuart Gall | 501,322 | Non-EMI |
| Nicholas Sleep | 450,297 | Non-EMI |
| Nicholas Sleep | 530,428 | EMI |
| Helen Jones | 334,409 | Non-EMI |
| Helen Jones | 302,131 | EMI |
Following the option grants above, the Directors hold the total number of share options as shown below:
| Director | Number of options held |
| Stuart Gall | 4,880,048 |
| Nicholas Sleep | 3,879,436 |
| Helen Jones | 2,298,806 |
|
| 11,058,490 |
| % of share capital on fully diluted basis | 3.1% |
Vesting criteria for all options
The share options vest equally over three years i.e. one third on the first, second and third anniversary of issue, subject to the grantee's continued service with the Group and will remain exercisable at any point up until the tenth anniversary of the date of grant.
| Number of shares in respect of which the Option shall vest |
| 1/3 vest after 12 months |
| 1/3 vest after a further 12 months |
| 1/3 vest after a further 12 months |
Management and employee options
A total of 6,800,332 options have been issued to other management and employees. These option grants are under the Company's EMI scheme where the individual and the grant meets EMI criteria. Grants which do not qualify are under the same rules as the EMI scheme but will not benefit from EMI tax status.
The notification in Appendix 1 to this announcement, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
For further information, please contact:
| Intelligent Ultrasound Group plc | |
| Stuart Gall, CEO | Tel: +44 (0)29 2075 6534 |
| Helen Jones, CFO | |
| | |
| Cavendish Capital Markets Limited - Nominated Adviser and Broker | |
| Giles Balleny/Dan Hodkinson (Corporate Finance) | Tel:? +44 (0)20 7220 0500 |
| Michael Johnson/Julian Morse (Sales) Nigel Birks (ECM) | |
| | |
| TB Cardew - PR Advisors Ed Orlebar | Intelligentultrasound@tbcardew.com Tel: +44 (0)7738 724630 |
| Allison Connolly | Tel: +44 (0)7587 453955 |
| Emma Pascoe-Watson | Tel: +44 (0)7774 620415 |
| | |
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:
Simulation
Real-time hi-fidelity ultrasound education and training through simulation. Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,500 simulators have been sold to over 750 medical institutions around the world.
Clinical AI software
Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE Healthcare's SonoLyst software that is incorporated in their Voluson Expert 22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB.
NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the FDA, but is not available for sale in any other territory requiring government approval for this type of product.
Appendix 1
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
| NOTIFICATION OF TRANSACTIONS OF PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES | ||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Stuart Gall |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Full name of the entity | Intelligent Ultrasound Group plc |
| b) | Legal entity identifier code | 213800K4ZVWL4ZYQAZ70 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument | Options over ordinary shares in Intelligent Ultrasound Group plc with a nominal value of 1 pence each |
| b) | Identification Code | ISIN: GB00BN791Q39 |
| c) | Nature of the transaction | Grant of options over Ordinary Shares |
| d) | Currency | GBP - British pound |
| e) | Price(s) and Volume(s) |
Price - 9.6 pence Volume - 1,031,750 |
| f) | Aggregated information - Price - Volume - Total | N/A |
| g) | Date of transaction | 21 December 2023 |
| h) | Place of transaction | Off market |
| NOTIFICATION OF TRANSACTIONS OF PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES | ||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Nicholas Sleep |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Technical Officer |
| b) | Initial notification/amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Full name of the entity | Intelligent Ultrasound Group plc |
| b) | Legal entity identifier code | 213800K4ZVWL4ZYQAZ70 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument | Options over ordinary shares in Intelligent Ultrasound Group plc with a nominal value of 1 pence each |
| b) | Identification Code | ISIN: GB00BN791Q39 |
| c) | Nature of the transaction | Grant of options over Ordinary Shares |
| d) | Currency | GBP - British pound |
| e) | Price(s) and Volume(s) |
Price - 9.6 pence Volume - 980,725 |
| f) | Aggregated information - Price - Volume - Total | N/A |
| g) | Date of transaction | 21 December 2023 |
| h) | Place of transaction | Off market |
| NOTIFICATION OF TRANSACTIONS OF PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES | ||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Helen Jones |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification/amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Full name of the entity | Intelligent Ultrasound Group plc |
| b) | Legal entity identifier code | 213800K4ZVWL4ZYQAZ70 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument | Options over ordinary shares in Intelligent Ultrasound Group plc with a nominal value of 1 pence each |
| b) | Identification Code | ISIN: GB00BN791Q39 |
| c) | Nature of the transaction | Grant of options over Ordinary Shares |
| d) | Currency | GBP - British pound |
| e) | Price(s) and Volume(s) |
Price - 9.6 pence Volume - 636,540 |
| f) | Aggregated information - Price - Volume - Total | N/A |
| g) | Date of transaction | 21 December 2023 |
| h) | Place of transaction | Off market |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.